Ratios in Focus: Analyzing Augmedix Inc (AUGX)’s Price-to-Cash and Price-to-Free Cash Flow

In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.

In the latest session, Augmedix Inc (NASDAQ: AUGX) closed at $2.34 up 5.17% from its previous closing price of $2.22. In other words, the price has increased by $5.17 from its previous closing price. On the day, 0.56 million shares were traded. AUGX stock price reached its highest trading level at $2.37 during the session, while it also had its lowest trading level at $2.23.

Ratios:

For a deeper understanding of Augmedix Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.41 and its Current Ratio is at 2.41. In the meantime, Its Debt-to-Equity ratio is 1.11 whereas as Long-Term Debt/Eq ratio is at 0.83.

On December 15, 2023, Evercore ISI started tracking the stock assigning a In-line rating and target price of $6.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 15 ’24 when Shakil Ian sold 500 shares for $3.80 per share. The transaction valued at 1,900 led to the insider holds 3,000 shares of the business.

Shakil Ian sold 19,544 shares of AUGX for $74,590 on Apr 12 ’24. The CHIEF STRATEGY OFFICER now owns 3,000 shares after completing the transaction at $3.82 per share. On Apr 11 ’24, another insider, Shakil Ian, who serves as the CHIEF STRATEGY OFFICER of the company, sold 24,778 shares for $3.93 each. As a result, the insider received 97,477 and left with 3,000 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUGX now has a Market Capitalization of 114584416 and an Enterprise Value of 93679992. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.55 while its Price-to-Book (P/B) ratio in mrq is 4.88. Its current Enterprise Value per Revenue stands at 2.089 whereas that against EBITDA is -5.298.

Stock Price History:

The Beta on a monthly basis for AUGX is 0.46, which has changed by -0.3922078 over the last 52 weeks, in comparison to a change of 0.2704494 over the same period for the S&P500. Over the past 52 weeks, AUGX has reached a high of $6.25, while it has fallen to a 52-week low of $2.22. The 50-Day Moving Average of the stock is -32.75%, while the 200-Day Moving Average is calculated to be -49.18%.

Shares Statistics:

For the past three months, AUGX has traded an average of 379.87K shares per day and 409880 over the past ten days. A total of 48.61M shares are outstanding, with a floating share count of 43.96M. Insiders hold about 10.23% of the company’s shares, while institutions hold 74.70% stake in the company. Shares short for AUGX as of 1714435200 were 1688497 with a Short Ratio of 4.44, compared to 1711584000 on 831537. Therefore, it implies a Short% of Shares Outstanding of 1688497 and a Short% of Float of 6.41.

Earnings Estimates

The market rating for Augmedix Inc (AUGX) is a result of the insights provided by 5.0 analysts actively involved in the assessment.On average, analysts expect EPS of -$0.13 for the current quarter, with a high estimate of -$0.11 and a low estimate of -$0.17, while EPS last year was -$0.14. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.11 and low estimates of -$0.15.

Analysts are recommending an EPS of between -$0.44 and -$0.58 for the fiscal current year, implying an average EPS of -$0.51. EPS for the following year is -$0.35, with 4.0 analysts recommending between -$0.27 and -$0.44.

Revenue Estimates

A total of 6 analysts believe the company’s revenue will be $13.37M this quarter.It ranges from a high estimate of $13.5M to a low estimate of $13.1M. As of the current estimate, Augmedix Inc’s year-ago sales were $9.63MFor the next quarter, 6 analysts are estimating revenue of $14.59M. There is a high estimate of $14.7M for the next quarter, whereas the lowest estimate is $14.4M.

A total of 6 analysts have provided revenue estimates for AUGX’s current fiscal year. The highest revenue estimate was $62M, while the lowest revenue estimate was $60.34M, resulting in an average revenue estimate of $61.15M. In the same quarter a year ago, actual revenue was $44.85MBased on 5 analysts’ estimates, the company’s revenue will be $85.1M in the next fiscal year. The high estimate is $87M and the low estimate is $83.39M.

Most Popular

[the_ad id="945"]